Efficacy and safety of bevacizumab plus erlotinib versus bevacizumab or erlotinib alone in the treatment of non-small-cell lung cancer: a systematic review and meta-analysis

OBJECTIVES: Bevacizumab and erlotinib inhibit different tumour growth pathways, and both exhibit beneficial effects in the treatment of non-small-cell lung cancer (NSCLC). However, the efficacy of bevacizumab in combination with erlotinib remains controversial. Therefore, we conducted a meta-analysi...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:BMJ Open
Egile Nagusiak: Zhang, Shu, Mao, Xiao-dong, Wang, Hai-tao, Cai, Feng, Xu, Jing
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BMJ Publishing Group 2016
Gaiak:
Oncology
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4932259/
https://ncbi.nlm.nih.gov/pubmed/27363819
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjopen-2016-011714
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak